Tilray Brands (NASDAQ:TLRY) Trading Down 3.7% - Here's Why

Key Points

• Tilray shares were down 3.7%, trading around $6.95 on Thursday with roughly 2.42 million shares changing hands—about 39% below the stock's average daily volume.
• The company announced a strategic alliance to access Alliance Healthcare Deutschland's network (27 logistics centers, >10,000 pharmacies) to boost pharmacy distribution in Germany and also expanded its beverage lineup with the new Pub Light SKU to diversify revenue beyond cannabis.
• Analysts hold a consensus "Hold" rating with a $13.33 average price target; Tilray beat Q results (EPS -$0.02 vs. -$0.14 est., revenue $217.5M) but still reports deeply negative net margins and a negative return on equity.

Tilray Brands, Inc. (NASDAQ:TLRY - Get Free Report)'s stock price was down 3.7% during trading on Thursday . The stock traded as low as $6.93 and last traded at $6.95. Approximately 2,415,825 shares were traded during trading, a decline of 39% from the average daily volume of 3,978,633 shares. The stock had previously closed at $7.22.

Tilray Brands News Roundup

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Pharma announced a strategic alliance with Tilray Medical, CC Pharma, 14U Pharma and the “gesund leben” cooperation (operated by Alliance Healthcare Deutschland) to expand pharmacy distribution across Germany — access to Alliance’s network (27 logistics centers, >10,000 pharmacies) could accelerate prescription and OTC pharmaceutical sales in a large EU market and reduce go‑to‑market friction. Article Title
• Positive Sentiment: Tilray’s beverage arm expanded its product lineup with Pub Light, a 99-calorie, 4% ABV light lager under the Pub Beer/Cheap Fun banner — product innovation and broader SKU presence support on‑premise and retail distribution growth in the U.S. beverage segment and help diversify revenue away from cannabis alone, though near‑term sales impact will be modest. Article Title
• Neutral Sentiment: Brokerages maintain a consensus "Hold" rating on TLRY, signaling analyst caution and limited near‑term upside despite recent operational announcements; this can mute investor reaction to positive commercial news until revenue and margin improvements become clearer. Article Title

Analyst Ratings Changes

Several brokerages recently weighed in on TLRY. Zacks Research upgraded shares of Tilray Brands from a "strong sell" rating to a "hold" rating in a report on Wednesday, February 11th. Canaccord Genuity Group started coverage on shares of Tilray Brands in a report on Tuesday, January 27th. They set a "hold" rating for the company. Wall Street Zen cut shares of Tilray Brands from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. ATB Cormark Capital Markets upgraded Tilray Brands from a "strong sell" rating to a "hold" rating in a research report on Wednesday, December 10th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tilray Brands in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $13.33.

Tilray Brands Stock Down 3.7%

The business's 50-day moving average is $8.18 and its two-hundred day moving average is $10.87. The firm has a market capitalization of $809.74 million, a price-to-earnings ratio of -0.31 and a beta of 1.96. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.72 and a current ratio of 2.81.

Tilray Brands (NASDAQ:TLRY - Get Free Report) last issued its quarterly earnings data on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.12. The firm had revenue of $217.51 million during the quarter, compared to analysts' expectations of $211.15 million. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. During the same quarter in the previous year, the company earned ($0.03) earnings per share. On average, equities analysts anticipate that Tilray Brands, Inc. will post -0.2 earnings per share for the current year.

Institutional Trading of Tilray Brands

Hedge funds have recently added to or reduced their stakes in the business. Alpine Global Management LLC acquired a new position in Tilray Brands in the fourth quarter valued at about $169,000. Voloridge Investment Management LLC acquired a new stake in shares of Tilray Brands during the fourth quarter worth about $824,000. Polymer Capital Management US LLC acquired a new stake in shares of Tilray Brands during the fourth quarter worth about $1,058,000. Engineers Gate Manager LP bought a new position in shares of Tilray Brands during the 4th quarter valued at about $126,000. Finally, Schonfeld Strategic Advisors LLC grew its position in shares of Tilray Brands by 4.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company's stock valued at $1,304,000 after purchasing an additional 6,182 shares during the period. Institutional investors and hedge funds own 9.35% of the company's stock.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.